Info

VIVUS, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity, for which the pivotal Phase III studies have been initiated; Qnexa for treating diabetes, which is in Phase II clinical trials; Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a Phase II study has been completed, and Avanafil is being developed for the treatment of erectile dysfunction; for which Phase II studies have been completed. The Company also markets MUSE as a prescription product for the treatment of erectile dysfunction. The Company's former investigational product, Evamist, a metered dose transdermal estradiol spray approved for the treatment of vasomotor symptoms associated with menopause, was sold to K-V Pharmaceutical Company (K-V) on May 15, 2007.(Source: 10-K)